Mean and standard deviation of the three dimensions and of the global score of STS after COVID-19. by Martina Gnerre (12329356)

Growth of cell monolayers and 3D spheroids under different concentrations of HIF inhibitor YC-1 in growth media. by Sreerupa Sarkar (9628788)

Decreased respiratory performance of children and adolescents with myelomeningocele who use a wheelchair – preliminary data by E.J. Martins (7141313)

List of 29 covariates selected from a list of 71 variables using recursive feature elimination and further selection of 17 uncorrelated covariates (shaded grey). by Dennis Ochola (11626912)

Subjects:

Mean (±95%CI) 24-hr post soreness measured using a numeric pain rating scale (1–10) for the Nordic hamstring exercise, Sprint, and control groups. by Nicholas J. Ripley (14709756)

Validation of genetic markers for risk of OA or knee OA for decrease in minJSW. by Mieke L. M. Bentvelzen (21594442)

Deletion of TAL does not decrease GNG flux. by Julie Kovářová (4114573)

Image 5_Behavioral and biochemical changes associated with the analgesic effects of (2R,6R)-hydroxynorketamine alone and in combination with meloxicam following disk puncture in mi... by Vaskar Das (21529538)

“…EC₅₀ estimates for (2R,6R)-Hydroxynorketamine were 14.2 mg/kg (95% CI: 10.3 mg/kg to 19.7 mg/kg) in male and 16.9 mg/kg (95% CI: 12.8 mg/kg to 22.3 mg/kg) in female mice (P < 0.637). (2R,6R)-Hydroxynorketamine plus meloxicam enhanced the analgesic effect on the AUC_0−3d of meloxicam alone. (2R,6R)-Hydroxynorketamine analgesia was associated with increases in Glutamate receptor A1 & A2, p-Kv2.1, p-CaMKII and reduced BDNF protein ratios in the hippocampus, attenuated c-Fos in the spinal cord, and decreased BDNF at the dorsal root ganglion (DRG).…”

Follow-up characteristics of ART-experienced people living with HIV-2 five years following virologic success in West Africa (N = 95). by Jean J. Koffi (20988337)

Subjects:

Table_1_v2_A long waiting time from diagnosis to treatment decreases the survival of non-small cell lung cancer patients with stage IA1: A retrospective study.docx by Bin Liu (5899)

“…Objective<p>The prognostic effect of delayed treatment on stage IA1 non-small cell lung cancer (NSCLC) patients is still unclear. …”

Data_Sheet_1_Concurrent use of statins decreases major bleeding and intracerebral hemorrhage in non-valvular atrial fibrillation patients taking direct oral anticoagulants—A nation... by Hsin-Hsu Wu (440386)

“…</p>Results<p>50,854 (56.0%) of them were male with a mean age of 74.9 (SD, 10.4) years. …”

Table_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to... by Ming-Ling Chang (44638)

“…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”

Image_1_Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to... by Ming-Ling Chang (44638)

“…Patients with baseline cirrhosis (2.78 ± 2.56 vs. 6.84 ± 9.00 mg/dL, p=0.024) and UDCA nonresponders (2.54 ± 2.19 vs. 4.51 ± 6.99 mg/dL, p=0.006) had increased total bilirubin levels while patients without cirrhosis (AST: 91.5 ± 84.5 vs. 58.9 ± 43.7 U/L, p<0.001; ALT: 107.3 ± 122.5 vs. 50.7 ± 36.8 U/L, p<0.001) and UDCA responders (AST: 83.8 ± 101.3 vs. 45.58 ± 38.42 U/L, p=0.014; ALT: 95.10 ± 144.6 vs. 39.12 ± 30.65 U/L, p=0.009) had decreased aminotransferase levels. …”

Madrasin decreases transcription of protein-coding genes. by Michael Tellier (8284752)

Madrasin decreases transcription of protein-coding genes. by Michael Tellier (8284752)

Pharmacological Mechanism of the Non-hallucinogenic 5‑HT_2A Agonist Ariadne and Analogs by Michael J. Cunningham (14267038)

“…Ariadne is a non-hallucinogenic analog in the phenylalkylamine chemical class of psychedelics that is closely related to an established synthetic hallucinogen, 2,5-dimethoxy-4-methyl-amphetamine (DOM), differing only by one methylene group in the α-position to the amine. …”

Pharmacological Mechanism of the Non-hallucinogenic 5‑HT_2A Agonist Ariadne and Analogs by Michael J. Cunningham (14267038)

“…Ariadne is a non-hallucinogenic analog in the phenylalkylamine chemical class of psychedelics that is closely related to an established synthetic hallucinogen, 2,5-dimethoxy-4-methyl-amphetamine (DOM), differing only by one methylene group in the α-position to the amine. …”

Cumulative effects and geographic distribution of mCHG-decreasing alleles. by Eriko Sasaki (501178)

“…The insert shows the six observed genotypes with three mCHG-decreasing and the <i>NRPE1’</i> non-reference allele. …”

Cellular uptake of [¹⁴C]docosahexaenoic acid (DHA) by RBECs transfected with MFSD2A siRNA. by Takuro Iwao (14636741)

Dose response of airways to Methacholine shows a decreased contractility in <i>GSTCD</i>^-/- mouse lungs following LPS treatment. by Bo Liu (127343)